
Leqembi’s Real Advantage Isn’t the Drug — It’s the Network
The diagnostic and treatment network behind Leqembi may be its biggest competitive edge.

The diagnostic and treatment network behind Leqembi may be its biggest competitive edge.

New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.

A safer Alzheimer’s treatment may be on the horizon — but families still have meaningful choices today.

Many diagnosed patients won’t qualify — here are the
7 medical criteria.

New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.

In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.

New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.

Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.

New studies highlight smoother tolerability, easier routines, and practical safety updates that make the rivastigmine patch an increasingly caregiver-friendly option.

Three major GLP-1 trials came out in late 2025. One weight-loss drug slowed early Alzheimer’s decline, while two others failed. Surprisingly, this mixed pattern may point the way toward a promising new treatment direction.

After years of research into nutrition and dementia, no single diet has been the focus of as many positive studies as The Mediterranean Diet.

Researchers say it takes a dozen “intervention sessions” to improve cognition in those at risk for Alzheimer’s and other dementias.

FDA-approved Sargramostim, a normal human protein, improved memory and cognition in Alzheimer’s patients in a Phase II clinical trial. The drug is safe and well-tolerated, and has been used for other disorders for 30 years.

Researchers say it takes a dozen “intervention sessions” to improve cognition in those at risk for Alzheimer’s and other dementias.

FDA-approved Sargramostim, a normal human protein, improved memory and cognition in Alzheimer’s patients in a Phase II clinical trial. The drug is safe and well-tolerated, and has been used for other disorders for 30 years.

This carpool sing-a-long between a father with dementia and his son went viral. $50,000 in donations poured into the Alzheimer’s Society. Enjoy their great music. Sing along if you can!

Verna and Jerry Kinersly were happily married for nearly 68 years. See why they were glad to have found the Lou Ruvo Center for Brain Health.
No spam, only news and updates.


